SUNNYVALE, Calif., May 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) is pleased to announce that Gregory R. Wade has joined the company as Executive Vice President of Business Development. In his position, Greg will further establish the Business Development department and lead all Business Development and Competitive Intelligence efforts.
Greg is a biopharmaceutical industry veteran with over 20 years of experience and previously held leadership roles most recently as a Managing Director of Healthcare Equity Research at Wedbush Pac Grow Life Sciences. During his career at Wedbush, Greg covered over 50 life sciences companies. Greg received his PhD in Physiology from the University of Western Ontario. At the beginning of his professional career he gained valuable experiences with a venture capital fund and within corporate and business development for two biopharmaceutical companies.
"Greg Wade has a tremendous amount of experience evaluating the market potential of small molecules and the business viability of life science platform technologies," said Bob Duggan. "It is our mission to build a viable biopharmaceutical company which is focused on patient friendly, body harmonious therapies which improve quality and duration of life. I am looking forward to the contributions Greg will make to our team by identifying promising product candidates in support of this mission. We are very excited to leverage Greg's skill in this important aspect of our company's long term success."
Pharmacyclics® is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify and control promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.
Pharmacyclics markets IMBRUVICA and has three product candidates in clinical development and several preclinical molecules in lead optimization. The company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.
Pharmacyclics is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at www.pharmacyclics.com.
SOURCE Pharmacyclics, Inc.